Moreover, we also found that GLRX expression was significantly higher in glioma patients with malignant molecular phenotypes, including those harboring the IDH wild-type state, 1p/19q non-codeletion state, and MGMT unmethylated promoters. This evidence concerns the gene GLRX and central nervous system cancer.